Search Cancer Clinical Trials

Mass General Brigham Cancer Institute offers patients access to a wide variety of clinical trials of promising new therapies. Use the search tool to find open protocols for your type of cancer.
Search by condition
Search By:
100 results
  • Lung Cancer

24-690          Phase I

A Phase 1, Multicenter, Open-Label, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of YL201 in Patients With Advanced Solid Tumors

  • Pancreatic Cancer, Colorectal Cancer, Lung Cancer

25-022          Phase I

A Phase 1, Open-Label Dose Escalation and Expansion Study of PT0253 in Participants with KRAS G12D Mutated Advanced Solid Tumors

  • Ovarian Cancer, Breast Cancer, Cervical Cancer, Endometrial Cancer

25-490          Phase I

A Phase 1, Open-Label Dose Escalation and Expansion Study of SNV4818 as Monotherapy or in Combination with other Anticancer Agents in Participants with Advanced Solid Tumors

  • Head and Neck Cancer, Melanoma

23-589          Phase I

A Phase 1, Open-Label, Dose Escalation Study of the Safety and Tolerability of ANK-101 in Advanced Solid Tumors

  • Prostate Cancer

25-058          Phase I

A Phase 1, Open-Label, Multicenter Study of JANX007 in Subjects with Metastatic Castration-Resistant Prostate Cancer

  • Prostate Cancer, Pancreatic Cancer, Melanoma, Lung Cancer, Head and Neck Cancer, Gastric (Stomach) Cancer, Esophageal Cancer, Colorectal Cancer, Cervical Cancer, Breast Cancer, Bladder Cancer, Ovarian Cancer

25-287          Phase I

A Phase 1, Open-label, Multi-center Study of the Safety, Tolerability, and Efficacy of IPH4502 as a Single Agent in Advanced Solid Tumors

  • Brain Tumors

22-532          Phase I

A Phase 1, Safety Lead-in and Randomized, Open-label, Perioperative Study of Vorasidenib in Combination with Pembrolizumab in Subjects with Recurrent or Progressive Enhancing IDH-1 Mutant Astrocytomas

  • Pancreatic Cancer, Lung Cancer, Colorectal Cancer

25-375          Phase I

A Phase 1/1b, Open-Label, Multicenter, First-in-Human Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-Tumor Activity of VVD-159642, a RAS PI3Ka inhibitor, as a Single Agent and in Combination in Participants With Advanced Solid Tumors

  • Melanoma, Endometrial Cancer, Breast Cancer, Bladder Cancer, Ovarian Cancer, Uterine Cancer, Lung Cancer

22-430          Phase II

A Phase 1/2 First-in-Human Study of the Safety and Efficacy of IMC-F106C as a Single Agent and in Combination with Checkpoint Inhibitors in HLA-A*02:01-Positive Participants with Advanced PRAME-Positive Cancers

  • Pancreatic Cancer, Bladder Cancer, Endometrial Cancer, Esophageal Cancer, Sarcoma, Liver Cancer, Gastric (Stomach) Cancer

20-544          Phase II

A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients with Advanced Solid Tumors Harboring a p53 Y220C Mutation

Showing 1 - 10 of 100 results